Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

April’s top stories: GSK and MMV’s malaria drug, Novartis’s COPD trial

GlaxoSmithKline and Medicines for Malaria Venture (MMV) initiated a Phase III global programme to assess tafenoquine for treating and relapse prevention of Plasmodium vivax malaria, while Novartis has reported positive results from the Phase IV INSTEAD switch trial of Onbrez Breezhaler carried out in patients with chronic obstructive pulmonary disease (COPD). Drugdevelopment-technology.com wraps-up the key headlines from April 2014.

Go Top